Program
Anti-CLDN6/CD3 Bispecific Antibody XmAb541
Its studies are mostly in Ovarian Neoplasms, led by Xencor.
Furthest: phase 1, since Feb 16, 20242 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Xencor | 22 open or running | phase 1since Feb 16, 2024 | Feb 16, 2024 | Dec 2027phase 1 · NCT06276491 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 16, 2024First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT06276491 · 282 planned · United States, Belgium, Denmark and more
- May 11, 2026Phase 1 study in Ovarian NeoplasmsNCT07593092 · 90 planned · United States
Ahead
- Dec 2027Primary completion: phase 1 study in Ovarian NeoplasmsNCT06276491
- Dec 2028Primary completion: phase 1 study in Ovarian NeoplasmsNCT07593092
TargetBeta
“A bispecific antibody directed against both the tumor-associated antigen (TAA) claudin 6 (CLDN6; CLDN-6) and the T-cell surface antigen CD3, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-CLDN6/Anti-CD3 Bispecific Antibody BGB-B455rule | BeOne Medicines | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07593092Ovarian Neoplasms · United States | 1 | Recruiting | Dec 2028 | 90 |
| NCT06276491Ovarian Neoplasms · United States, Belgium, Denmark and more | 1 | Recruiting | Dec 2027 | 282 |
How it is read
Names in the registry
- “XmAb541”, 2 entries
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.